Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6766MR)

This product GTTS-WQ6766MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6766MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7091MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ8706MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ6112MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ14849MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ13807MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ5228MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ13106MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ15844MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-18087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW